---
anonymous_label: OUT-34
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
output_sha256: 9f13f8e55479ec9b1506e62ff9ccb55b68a244ef4eadf7c9ceb21c2a198fc391
condition_blinded: true
note: Condition-blinded model output for blind judging. The generating condition, run number, and seed are withheld by design.
---

# Output OUT-34

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

You are currently facing a classic "false positive" signal. Your executive team sees growth (expansion bookings, shortened cycles) and attributes it to product-market fit. However, the granular data suggests this growth is driven by **sales incentives** (bundle pricing) and **buyer aspiration** (the roadmap pitch), rather than **user utility**.

The risk is that you are scaling a "leaky bucket." The evidence of analysts falling back to manual notes, the inability of public-sector users to explain recommendations, and the quiet churn in regional accounts indicate that PlanPilot is currently a "management tool" (used for enablement and reviews) rather than a "workflow tool" (integrated into the analyst's daily habit).

Here is why the other options are insufficient or dangerous:
*   **Scale PlanPilot Broadly:** This is high-risk. If the core utility is missing, scaling will only accelerate churn once the "bundle price" honeymoon ends.
*   **Adoption Quality Sprint:** This measures *what* is happening (event tracking) but not *why*. You already know the usage patterns are skewed toward managers; more dashboards won't tell you why analysts abandon the tool.
*   **Demand Cleanroom:** This tests sales elasticity, not product value. It tells you if the product is sellable without discounts, but it doesn't tell you how to fix the product so that users actually keep it.
*   **Narrow to Public Sector:** This is premature. The public sector has specific "explainability" hurdles, but you don't yet know if the core engine is failing across all segments or just that specific one.

The **Case Evidence Review** is the only option that addresses the "truth gap." By auditing actual case files, you move from *proxy metrics* (usage pings) to *outcome metrics* (accepted vs. overridden suggestions). This reveals whether the "strong quarter" was a result of a great product or a great sales motion.

### The Recommendation
**Commit to the Case Evidence Review.** Use the next twelve days to define the sample set and the rubric for "accepted/overridden/impossible." This provides the empirical basis to decide—mid-year—whether to pivot the roadmap or double down on scaling.

### The Strongest Reason Against It
The Case Evidence Review is slow, manual, and "un-sexy" compared to the growth metrics the board currently loves. By choosing this, you are effectively telling the CEO and Board: *"The recent growth might be an illusion."* This risks damaging the current momentum and political capital the product team has gained by being seen as "commercially disciplined." You are trading a high-growth narrative for an uncomfortable truth.

### Observable Evidence That Would Change My Mind
I would switch my recommendation to **Scale PlanPilot Broadly** if you can produce evidence that the "manual notes" fallback is not a failure of the tool, but a requirement of the industry's compliance standards.

Specifically: if you find that analysts *do* accept PlanPilot’s recommendations but are *required* to transcribe them into manual notes for legal auditing purposes, then the product is already providing value—it just needs a "export to audit log" feature. In that case, the utility is proven, and you should scale immediately.
